The monoclonal antibody VYD2311 is in clinical trials for preventing COVID-19.
In this Research Letter, @ianmellis.bsky.social et al. report that a laboratory-synthesized version of it inhibits many SARS-CoV-2 variants in laboratory-based infection models: doi.org/10.1172/jci....